-
Product Insights
Duchenne Muscular Dystrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Duchenne Muscular Dystrophy - Drugs In Development, 2023’, provides an overview of the Duchenne Muscular Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Recessive X Chromosome Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Recessive X Chromosome Disorders - Drugs In Development, 2023’, provides an overview of the Recessive X Chromosome Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Recessive X Chromosome Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sebetralstat in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sebetralstat in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sebetralstat in Hereditary Angioedema (HAE)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amlitelimab in Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Amlitelimab in Asthma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Amlitelimab in Asthma Drug Details: Amlitelimab (KY-1005) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LEVI-04 in Osteoarthritis Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LEVI-04 in Osteoarthritis Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.LEVI-04 in Osteoarthritis Pain Drug Details:LEVI-04 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Paclitaxel Albumin Bound in Gastric Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Paclitaxel Albumin Bound in Gastric Cancer Drug Details: Paclitaxel albumin bound (Paclitaxel) is a cyclodecane...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBV-368 in Bladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABBV-368 in Bladder Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ABBV-368 in Bladder Cancer Drug Details:ABBV-368 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PM-54 in Liposarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PM-54 in Liposarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PM-54 in LiposarcomaDrug Details:PM-54 is under development for the treatment of urothelial carcinoma, clear...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Inclisiran in Coronary Artery Disease (CAD) (Ischemic Heart Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Inclisiran in Coronary Artery Disease (CAD) (Ischemic Heart Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Inclisiran in Coronary Artery Disease (CAD) (Ischemic...